Implantable cardioverter defibrillators for prevention of sudden cardiac death
Medical Services Advisory Committee
Record ID 32007000062
English
Authors' objectives:
The aim of this report is to systematically review the literature on the use of implantable cardioverter defibrillators for prevention of sudden cardiac death.
Authors' recommendations:
On the strength of evidence relating to safety, effectiveness and cost effectiveness, MSAC concludes that the use of implantable cardioverter defibrillators for the primary prevention of sudden cardiac death is beneficial and appropriate for: 1. patients with a left-ventricular ejection fraction of less than or equal to 30 per cent at least one month after a myocardial infarct when the patient has received optimal medical therapy. 2. patients with chronic heart failure associated with mild to moderate symptoms (NYHA II and III) and a left-ventricular ejection fraction less than or equal to 35 per cent when the patient has received optimal medical therapy.
On the strength of evidence relating to safety, effectiveness and cost effectiveness, MSAC concludes that the use of combined implantable cardiac resynchronisation and cardioverter defibrillator therapy is beneficial and appropriate for patients with chronic heart failure associated with moderate to severe symptoms (NYHA III and IV), sinus rhythm, a leftventricular ejection fraction of less than or equal to 35 per cent and a QRS duration greater than or equal to 120ms, when the patient has received optimal medical therapy.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.msac.gov.au/
Year Published:
2006
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Australia
MeSH Terms
- Costs and Cost Analysis
- Defibrillators, Implantable
Contact
Organisation Name:
Medical Services Advisory Committee
Contact Address:
MSAC (MDP 107), GPO Box 9848, Canberra, ACT 2601, Australia. Tel: +61 2 6289 6811; Fax: +61 2 6289 8799.
Contact Name:
msac.secretariat@health.gov.au
Contact Email:
msac.secretariat@health.gov.au
Copyright:
Medical Services Advisory Committee (MSAC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.